Compare DraftKings Inc (DKNG) vs 10X Genomics Inc (TXG) Price & Performance

DraftKings (DKNG) trades at $19.15, down 3.04% on the day and near its 52-week low of $18.95, reflecting bearish technical momentum. Fundamentally, revenue grew to $6.05 billion in 2025 with a slight net profit of $3.71 million, but recent quarterly EPS misses and a negative net income margin of -2.68% for 2026 highlight profitability challenges. The stock's high P/E of 246.33 signals premium valuation despite operational improvements, including positive operating cash flow of $662.86 million in 2025.

The outlook is mixed: strong analyst consensus (75% buy ratings) and a $33.13 price target suggest upside potential from sportsbook growth and prediction market expansion, but risks include competitive pressures, regulatory uncertainty from Brazil's betting ban, and volatility from high valuation multiples. Investors face a trade-off between long-term growth prospects and near-term earnings instability.

10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.

TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.